National Academy Press / Ligand / J Health-Sys Pharm / Canadian Agency for Drugs / /
Country
Canada / United Kingdom / /
Event
Product Issues / FDA Phase / /
Facility
National Institute of Health / Institute of Medicine / /
IndustryTerm
treatment of osteoporosis / clinical assessment tool / therapy for breast cancer / osteoporosis treatment / Osteoporosis Prevention / therapy for prostate cancer / clinical risk assessment tool / /
MedicalCondition
Scope Osteoporosis / established primary osteoporosis / malabsorption syndromes / Compston J. Monitoring osteoporosis / hyperparathyroidism / Rheumatoid arthritis / Androgen deficiency / Hyperthyroidism / Estrogen deficiency / venous thromboembolic disease / correct postural hypotension / thromboembolic disease / bone resorption / particularly chronic glucocorticoid use** / prostate cancer / breast cancer / idiopathic male osteoporosis / Osteopenia / Celiac / cancer / disease / cardiac arrhythmias / Chronic / vitamin D deficiency / postmenopausal osteoporosis / exaggerated dorsal kyphosis / pain / chronic back pain / myocardial infarction / corticosteroid-induced osteoporosis / Osteoporosis / Dizziness / /
National Institute of Health / Canadian Agency for Drugs and Technologies / World Health Organization / Institute of Medicine / National Osteoporosis Foundation / office of Dietary Supplements / Canadian Association of Radiologists / Clinician / North American Menopause Society / Society of Obstetricians / /
Person
Brenda Nazare / Ray Absorptiometry / Alvaro N. Fernandes Moca Trevisani / George A. Cranney / Ann Intern / /
Position
Bone Miner / Menz HB / /
Product
vitamin K / vitamin D / Prescription Medication / Calcitonin injection / OP medication / prednisone / calcium / /
Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Scope Osteoporosis (OP) is a significant risk factor for fragility fracture. This guideline summarizes curre